pmid,title,journal,year,drug,disease
39973207,"Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N(4)-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir.",Free radical research,2025,Molnupiravir,Leukemia
37142661,Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).,Leukemia,2023,Molnupiravir,Leukemia
36912366,Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.,Leukemia & lymphoma,2023,Molnupiravir,Leukemia
36806152,Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.,British journal of haematology,2023,Molnupiravir,Leukemia
36691818,Molnupiravir is effective in patients with haematological malignancies.,International journal of cancer,2023,Molnupiravir,Leukemia
